Edwards SAPIEN 3 TAVR Demonstrates Clinical Superiority To Surgery In PARTNER II Study

Go back to Edwards SAPIEN 3 TAVR Demonstrates Clinical Superiority To Surgery In PARTNER II Study
Edwards Lifesciences (NYSE: EW) Delayed: 92.01 -2.43 (2.57%)
Previous Close $94.44    52 Week High $166.87 
Open $94.55    52 Week Low $72.20 
Day High $95.34    P/E 26.75 
Day Low $91.87    EPS $3.44 
Volume 6,044,686